Gilead Sciences (NQ:GILD)

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

Topics ETFs

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗

September 24, 2026

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗

Topics ETFs

September 24, 2026

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Topics ETFs

Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗

September 04, 2026

Via Chartmill

What's going on in today's after hours session: S&P500 movers ↗

August 27, 2026

Via Chartmill

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗

September 22, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Topics ETFs

1 Cash-Producing Stock on Our Buy List and 2 We Find Risky

September 22, 2026

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of...

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig ↗

September 21, 2026

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

September 16, 2026

Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief...

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances ↗

September 15, 2026

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors? ↗

Topics Intellectual Property

September 15, 2026

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Topics ETFs

September 15, 2026

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

September 15, 2026

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END

Via FinancialNewsMedia

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat

September 15, 2026

A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers

From MarketNewsUpdates.com

Via GlobeNewswire

If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗

September 10, 2026

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market...

Via Benzinga

Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth ↗

September 10, 2026

Gilead Sciences (NASDAQ:GILD) CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment...

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has...

Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode ↗

September 10, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

1 S&P 500 Stock on Our Buy List and 2 Facing Challenges

September 09, 2026

Topics Stocks

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

September 08, 2026

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? ↗

September 05, 2026

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗

September 02, 2026

The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.

Topics ETFs

FDA Approves Gilead's New Single Tablet HIV Regimen ↗

August 31, 2026

Via Benzinga

3 Unpopular Stocks with Open Questions

August 31, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗

August 28, 2026

VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

Topics ETFs

August 27, 2026

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

August 26, 2026

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting ↗

August 26, 2026

Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.

These healthcare leaders are unlikely to suspend their dividend programs.

3 Dividend Stocks to Hold for the Next 10 Years ↗

August 25, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

Topics Artificial Intelligence Intellectual Property

3 Unprofitable Stocks with Questionable Fundamentals

August 25, 2026